Several stories about access to public information have caught my eye in the past week. Whether it involves public health data from Florida, evidence in a federal criminal case or embargoes and favored access at a federal agency, it’s clear that journalists are facing obstacles in ensuring the public’s access to information.
In Rhode Island, a judge ruled in favor of a journalist seeking evidence presented in the trial of a doctor now “serving four life sentences for his role in operating a pain management clinic like a ‘pill mill.'” The U.S. Drug Enforcement Administration had refused to release the records since journalist Phil Eil requested them after the trial ended in 2011. Continue reading
Photo: Tina Reed, Washington Business Journal
More than 20 people came to the July 14, AHCJ chapter event in Washington, D.C., to learn about how technology affects health and what regulatory issues to watch out for.
The conversation was moderated by Politico Pro’s David Pittman (@David_Pittman), who covers health information technology. Pittman, who proposed the event, invited the panelists for their participation, and pitched the idea to the chapter co-chairs. The panelists were: Continue reading
The nation’s clinical laboratories have pushed back hard against a proposal by U.S. Food and Drug Administration in October 2014 that would regulate laboratory developed tests. More than a year later, the disagreement became more heated when the Association of Molecular Pathology (AMP) accused the FDA of fabricating examples in a November report on LDTs.
In the report, “The Public Health Evidence for FDA Oversight of Laboratory Developed Tests: 20 Case Studies,” the agency cited 20 examples of problematic LDTs, saying, “…these products may have caused or have caused actual harm to patients.” We covered this report in a blog post earlier this month.
But that’s just the beginning of the story, as Allison Proffitt, editorial director of BioITWorld, found. Continue reading
Sometime this year, the U.S. Food and Drug Administration is expected to issue guidance to clinical laboratories that produce lab-developed tests (LDTs). Clinical labs that offer LDTs, and associations that represent these labs, have criticized the FDA’s oversight proposal and are challenging the agency’s authority to regulate these tests.
Many of us will be writing about LDTs, their value to patients and the need for a review of how these tests are produced, whether the results are clinically valid, and whether their marketing claims are accurate. Continue reading
Baltimore Sun reporter Andrea McDaniels was surprised to learn about an off-label treatment for tooth decay that some dentists are using.
In the fight against decay-causing bacteria, some researchers call the agent, silver diamine fluoride, a “silver-fluoride bullet.”
They point to evidence suggesting that SDF is not only effective in halting the decay process but in preventing the development of new caries. The material is cheap and can be easily painted onto the affected tooth.
In this Q&A, McDaniels tells us more about her work on the story, and offers some insights into how she manages her busy health and medical beat at the Sun.